An open-label study of the effect of intravenous epothilone D [KOS 862] on treatment response in patients with metastatic breast cancer.

Trial Profile

An open-label study of the effect of intravenous epothilone D [KOS 862] on treatment response in patients with metastatic breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2010

At a glance

  • Drugs Epothilone D (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Actual initiation date (Nov 2003) added as reported by Roche record.
    • 19 Aug 2007 Status changed from in progress to completed.
    • 20 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top